Ressources

In this 7th week of containment and as end of confinement in France is announced for May 11th, I would first of all like to thank you on behalf of our teams for all the messages of support you have sent us since the beginning of the COVID-19 crisis.

Regarding the current circumstances, we at XenTech want you to know that we are taking the Covid-19 pandemia very seriously. We are closely monitoring the pandemic, following guidance and advice from the World Health Organization (WHO), and the French Government. 

A preclinical platform of mouse-transplanted human pediatric liver tumors to evaluate the efficacy of conventional and innovative anticancer therapy

Liver cancer patient-derived xenografts to improve disease management in childhood and adolescence: perspectives and challenges of personalized medicine

A panel of pediatric liver cancer patient-derived xenografts to improve stratification of children with hepatoblastoma

A new and fast in vitro screen to predict in vivo drug efficacy using cell primary culture from patient derived tumor established xenografts